Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmias.
Ranolazine, which was approved by the US Food and Drug Administration in January 2006, provides a mechanism of action to treat ischemia that has not hitherto been available. Ranolazine is effective in reducing manifestations of ischemia and angina, and it also holds potential promise to be effective in the management of left ventricular dysfunction, particularly diastolic dysfunction, and arrhythmias. This article provides an update on the available studies concerning the value of ranolazine across the spectrum of cardiovascular disease.
Stone
Peter H
PH
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115-6110, USA. pstone@partners.org
D000083:Acetanilides / Q000494:pharmacology / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D009202:Cardiomyopathies / Q000188:drug therapy; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D000069458:Ranolazine
D000083:Acetanilides; D010879:Piperazines; D000069458:Ranolazine